Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma In this trial, patients with recurrent small HCC (single lesion ≤5 cm) were randomly assigned to receive either SBRT or RFA.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback